Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study

Abstract Objectives Prospective optical coherence tomography (OCT) study of strut apposition and neointimal hyperplasia thickness (NIH) of a paclitaxel eluting stent (PES), (Infinium, Sahajanand Medical Technologies Pvt Ltd.). Background Few data exist concerning neointimal coverage of PES. Uncovere...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2011-09, Vol.151 (2), p.155-159
Hauptverfasser: Davlouros, Periklis A, Nikokiris, George, Karantalis, Vasileios, Mavronasiou, Eleni, Xanthopoulou, Ioanna, Damelou, Anastasia, Tsigkas, Grigorios, Alexopoulos, Dimitrios
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 159
container_issue 2
container_start_page 155
container_title International journal of cardiology
container_volume 151
creator Davlouros, Periklis A
Nikokiris, George
Karantalis, Vasileios
Mavronasiou, Eleni
Xanthopoulou, Ioanna
Damelou, Anastasia
Tsigkas, Grigorios
Alexopoulos, Dimitrios
description Abstract Objectives Prospective optical coherence tomography (OCT) study of strut apposition and neointimal hyperplasia thickness (NIH) of a paclitaxel eluting stent (PES), (Infinium, Sahajanand Medical Technologies Pvt Ltd.). Background Few data exist concerning neointimal coverage of PES. Uncovered and malapposed struts are more common following stenting in acute coronary syndromes (ACS) than in non-ACS lesions. Methods All consecutive patients with ACS, treated with the above PES for single native coronary lesions between August 2008 and January 2009, who consented to invasive follow-up with OCT at six months ( N = 13), were included. Results At 6 months no patient demonstrated angiographic restenosis. 3180 struts from 20 stents were analyzed, and 91.3% were covered with neointima (NIH 204.8 ± 159.5 μm). Standard statistics and least squares estimates (LSE) derived from a hierarchical ANCOVA model to take into account clustering effects are presented. Rate of uncovered struts was 8.6%, LSE 7.39 (95% CI 3.05–11.73), malapposed struts 2.2%, LSE 1.76 (95% CI 0.05–3.58), and protruding struts 2.9%, LSE 2.8 (95% CI 1.35–4.65). The proportion of uncovered malapposed struts was significantly higher compared to uncovered embedded struts (55.7% vs. 6.8%, p < 0.01). In total, 5 (25%) PES were fully covered by neointima. No intracoronary thrombus or clinical events were detected. Conclusions Six months after implantation of a specific PES in patients with ACS, most of the stents were only partially covered with neointima, especially at sites of strut malapposition or protrusion. These findings emphasize the need for optimal stent apposition during implantation and for prolonged dual antiplatelet therapy.
doi_str_mv 10.1016/j.ijcard.2010.05.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_887756830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527310003542</els_id><sourcerecordid>1221140287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-917bd92505d8df63775a18ee5a9d289f08881e8d30318d6ef18a62f7d41caef13</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEosvCGyDkC4LLLrYTJw6HSlXFP6mCA3C2XHuy6yWxg-1UzUPxjky6C0gc4GLL9m--Gc83RfGU0S2jrH512LqD0dFuOcUrKraUVveKFZNNtWGNqO4XK8SajeBNeVY8SulAkWhb-bA447Smgld8Vfz4CMH57AbdExNuIOodEO0tSRl8xjVOmehxDMllFzxJ7pYMwed9IrrLEIkbxl77rO9eQ0c0GbXpXda30BPop-z87iTmPNFmyoCJYvA6ziTN3sYwQHpNLjB6zM7c1bGHCN4AyWEIu6jHPaJ5svPj4kGn-wRPTvu6-Pr2zZfL95urT-8-XF5cbYyoRN60rLm2LRdUWGm7umwaoZkEELq1XLYdlVIykLakJZO2ho5JXfOusRUzGk_lunhx1B1j-D5BympwyUCPP4UwJSUlStYS49fFy3-SjHPGKsplg2h1RE0MKUXo1Bix73FWjKrFUnVQR0vVYqmiQqFhGPbslGG6HsD-DvrlIQLPT4BO2L4uam9c-sNVomxku-Q_P3KAnbtxEFUybmmzdRFMVja4_1XytwAa7RfLvsEM6RCm6NEVxVTiiqrPy_gt08dw8EqBlf4ERijaEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1221140287</pqid></control><display><type>article</type><title>Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Davlouros, Periklis A ; Nikokiris, George ; Karantalis, Vasileios ; Mavronasiou, Eleni ; Xanthopoulou, Ioanna ; Damelou, Anastasia ; Tsigkas, Grigorios ; Alexopoulos, Dimitrios</creator><creatorcontrib>Davlouros, Periklis A ; Nikokiris, George ; Karantalis, Vasileios ; Mavronasiou, Eleni ; Xanthopoulou, Ioanna ; Damelou, Anastasia ; Tsigkas, Grigorios ; Alexopoulos, Dimitrios</creatorcontrib><description>Abstract Objectives Prospective optical coherence tomography (OCT) study of strut apposition and neointimal hyperplasia thickness (NIH) of a paclitaxel eluting stent (PES), (Infinium, Sahajanand Medical Technologies Pvt Ltd.). Background Few data exist concerning neointimal coverage of PES. Uncovered and malapposed struts are more common following stenting in acute coronary syndromes (ACS) than in non-ACS lesions. Methods All consecutive patients with ACS, treated with the above PES for single native coronary lesions between August 2008 and January 2009, who consented to invasive follow-up with OCT at six months ( N = 13), were included. Results At 6 months no patient demonstrated angiographic restenosis. 3180 struts from 20 stents were analyzed, and 91.3% were covered with neointima (NIH 204.8 ± 159.5 μm). Standard statistics and least squares estimates (LSE) derived from a hierarchical ANCOVA model to take into account clustering effects are presented. Rate of uncovered struts was 8.6%, LSE 7.39 (95% CI 3.05–11.73), malapposed struts 2.2%, LSE 1.76 (95% CI 0.05–3.58), and protruding struts 2.9%, LSE 2.8 (95% CI 1.35–4.65). The proportion of uncovered malapposed struts was significantly higher compared to uncovered embedded struts (55.7% vs. 6.8%, p &lt; 0.01). In total, 5 (25%) PES were fully covered by neointima. No intracoronary thrombus or clinical events were detected. Conclusions Six months after implantation of a specific PES in patients with ACS, most of the stents were only partially covered with neointima, especially at sites of strut malapposition or protrusion. These findings emphasize the need for optimal stent apposition during implantation and for prolonged dual antiplatelet therapy.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2010.05.004</identifier><identifier>PMID: 20605242</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Acute Coronary Syndrome - diagnosis ; Acute Coronary Syndrome - surgery ; Antineoplastic Agents, Phytogenic - pharmacology ; Apposition ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiovascular ; Coronary Angiography ; Coronary heart disease ; Coronary Restenosis - diagnosis ; Coronary Restenosis - etiology ; Data processing ; Diagnosis, Differential ; Disease Progression ; Drug-Eluting Stents - adverse effects ; Female ; Follow-Up Studies ; Heart ; Humans ; Hyperplasia ; Implants ; Malapposition ; Male ; Medical sciences ; Middle Aged ; Myocarditis. Cardiomyopathies ; Neointima ; Neointima - complications ; Neointima - pathology ; OCT ; Paclitaxel ; Paclitaxel - pharmacology ; Prognosis ; Prospective Studies ; Prosthesis Failure ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; restenosis ; Statistical analysis ; Statistics ; Thrombosis ; Time Factors ; Tomography ; Tomography, Optical Coherence - methods ; Tunica Intima - pathology</subject><ispartof>International journal of cardiology, 2011-09, Vol.151 (2), p.155-159</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-917bd92505d8df63775a18ee5a9d289f08881e8d30318d6ef18a62f7d41caef13</citedby><cites>FETCH-LOGICAL-c545t-917bd92505d8df63775a18ee5a9d289f08881e8d30318d6ef18a62f7d41caef13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2010.05.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24537897$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20605242$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davlouros, Periklis A</creatorcontrib><creatorcontrib>Nikokiris, George</creatorcontrib><creatorcontrib>Karantalis, Vasileios</creatorcontrib><creatorcontrib>Mavronasiou, Eleni</creatorcontrib><creatorcontrib>Xanthopoulou, Ioanna</creatorcontrib><creatorcontrib>Damelou, Anastasia</creatorcontrib><creatorcontrib>Tsigkas, Grigorios</creatorcontrib><creatorcontrib>Alexopoulos, Dimitrios</creatorcontrib><title>Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Abstract Objectives Prospective optical coherence tomography (OCT) study of strut apposition and neointimal hyperplasia thickness (NIH) of a paclitaxel eluting stent (PES), (Infinium, Sahajanand Medical Technologies Pvt Ltd.). Background Few data exist concerning neointimal coverage of PES. Uncovered and malapposed struts are more common following stenting in acute coronary syndromes (ACS) than in non-ACS lesions. Methods All consecutive patients with ACS, treated with the above PES for single native coronary lesions between August 2008 and January 2009, who consented to invasive follow-up with OCT at six months ( N = 13), were included. Results At 6 months no patient demonstrated angiographic restenosis. 3180 struts from 20 stents were analyzed, and 91.3% were covered with neointima (NIH 204.8 ± 159.5 μm). Standard statistics and least squares estimates (LSE) derived from a hierarchical ANCOVA model to take into account clustering effects are presented. Rate of uncovered struts was 8.6%, LSE 7.39 (95% CI 3.05–11.73), malapposed struts 2.2%, LSE 1.76 (95% CI 0.05–3.58), and protruding struts 2.9%, LSE 2.8 (95% CI 1.35–4.65). The proportion of uncovered malapposed struts was significantly higher compared to uncovered embedded struts (55.7% vs. 6.8%, p &lt; 0.01). In total, 5 (25%) PES were fully covered by neointima. No intracoronary thrombus or clinical events were detected. Conclusions Six months after implantation of a specific PES in patients with ACS, most of the stents were only partially covered with neointima, especially at sites of strut malapposition or protrusion. These findings emphasize the need for optimal stent apposition during implantation and for prolonged dual antiplatelet therapy.</description><subject>Acute Coronary Syndrome - diagnosis</subject><subject>Acute Coronary Syndrome - surgery</subject><subject>Antineoplastic Agents, Phytogenic - pharmacology</subject><subject>Apposition</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Coronary Angiography</subject><subject>Coronary heart disease</subject><subject>Coronary Restenosis - diagnosis</subject><subject>Coronary Restenosis - etiology</subject><subject>Data processing</subject><subject>Diagnosis, Differential</subject><subject>Disease Progression</subject><subject>Drug-Eluting Stents - adverse effects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Implants</subject><subject>Malapposition</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Neointima</subject><subject>Neointima - complications</subject><subject>Neointima - pathology</subject><subject>OCT</subject><subject>Paclitaxel</subject><subject>Paclitaxel - pharmacology</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Prosthesis Failure</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>restenosis</subject><subject>Statistical analysis</subject><subject>Statistics</subject><subject>Thrombosis</subject><subject>Time Factors</subject><subject>Tomography</subject><subject>Tomography, Optical Coherence - methods</subject><subject>Tunica Intima - pathology</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks9u1DAQxiMEosvCGyDkC4LLLrYTJw6HSlXFP6mCA3C2XHuy6yWxg-1UzUPxjky6C0gc4GLL9m--Gc83RfGU0S2jrH512LqD0dFuOcUrKraUVveKFZNNtWGNqO4XK8SajeBNeVY8SulAkWhb-bA447Smgld8Vfz4CMH57AbdExNuIOodEO0tSRl8xjVOmehxDMllFzxJ7pYMwed9IrrLEIkbxl77rO9eQ0c0GbXpXda30BPop-z87iTmPNFmyoCJYvA6ziTN3sYwQHpNLjB6zM7c1bGHCN4AyWEIu6jHPaJ5svPj4kGn-wRPTvu6-Pr2zZfL95urT-8-XF5cbYyoRN60rLm2LRdUWGm7umwaoZkEELq1XLYdlVIykLakJZO2ho5JXfOusRUzGk_lunhx1B1j-D5BympwyUCPP4UwJSUlStYS49fFy3-SjHPGKsplg2h1RE0MKUXo1Bix73FWjKrFUnVQR0vVYqmiQqFhGPbslGG6HsD-DvrlIQLPT4BO2L4uam9c-sNVomxku-Q_P3KAnbtxEFUybmmzdRFMVja4_1XytwAa7RfLvsEM6RCm6NEVxVTiiqrPy_gt08dw8EqBlf4ERijaEQ</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Davlouros, Periklis A</creator><creator>Nikokiris, George</creator><creator>Karantalis, Vasileios</creator><creator>Mavronasiou, Eleni</creator><creator>Xanthopoulou, Ioanna</creator><creator>Damelou, Anastasia</creator><creator>Tsigkas, Grigorios</creator><creator>Alexopoulos, Dimitrios</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study</title><author>Davlouros, Periklis A ; Nikokiris, George ; Karantalis, Vasileios ; Mavronasiou, Eleni ; Xanthopoulou, Ioanna ; Damelou, Anastasia ; Tsigkas, Grigorios ; Alexopoulos, Dimitrios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-917bd92505d8df63775a18ee5a9d289f08881e8d30318d6ef18a62f7d41caef13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acute Coronary Syndrome - diagnosis</topic><topic>Acute Coronary Syndrome - surgery</topic><topic>Antineoplastic Agents, Phytogenic - pharmacology</topic><topic>Apposition</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Coronary Angiography</topic><topic>Coronary heart disease</topic><topic>Coronary Restenosis - diagnosis</topic><topic>Coronary Restenosis - etiology</topic><topic>Data processing</topic><topic>Diagnosis, Differential</topic><topic>Disease Progression</topic><topic>Drug-Eluting Stents - adverse effects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Implants</topic><topic>Malapposition</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Neointima</topic><topic>Neointima - complications</topic><topic>Neointima - pathology</topic><topic>OCT</topic><topic>Paclitaxel</topic><topic>Paclitaxel - pharmacology</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Prosthesis Failure</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>restenosis</topic><topic>Statistical analysis</topic><topic>Statistics</topic><topic>Thrombosis</topic><topic>Time Factors</topic><topic>Tomography</topic><topic>Tomography, Optical Coherence - methods</topic><topic>Tunica Intima - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davlouros, Periklis A</creatorcontrib><creatorcontrib>Nikokiris, George</creatorcontrib><creatorcontrib>Karantalis, Vasileios</creatorcontrib><creatorcontrib>Mavronasiou, Eleni</creatorcontrib><creatorcontrib>Xanthopoulou, Ioanna</creatorcontrib><creatorcontrib>Damelou, Anastasia</creatorcontrib><creatorcontrib>Tsigkas, Grigorios</creatorcontrib><creatorcontrib>Alexopoulos, Dimitrios</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davlouros, Periklis A</au><au>Nikokiris, George</au><au>Karantalis, Vasileios</au><au>Mavronasiou, Eleni</au><au>Xanthopoulou, Ioanna</au><au>Damelou, Anastasia</au><au>Tsigkas, Grigorios</au><au>Alexopoulos, Dimitrios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>151</volume><issue>2</issue><spage>155</spage><epage>159</epage><pages>155-159</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Abstract Objectives Prospective optical coherence tomography (OCT) study of strut apposition and neointimal hyperplasia thickness (NIH) of a paclitaxel eluting stent (PES), (Infinium, Sahajanand Medical Technologies Pvt Ltd.). Background Few data exist concerning neointimal coverage of PES. Uncovered and malapposed struts are more common following stenting in acute coronary syndromes (ACS) than in non-ACS lesions. Methods All consecutive patients with ACS, treated with the above PES for single native coronary lesions between August 2008 and January 2009, who consented to invasive follow-up with OCT at six months ( N = 13), were included. Results At 6 months no patient demonstrated angiographic restenosis. 3180 struts from 20 stents were analyzed, and 91.3% were covered with neointima (NIH 204.8 ± 159.5 μm). Standard statistics and least squares estimates (LSE) derived from a hierarchical ANCOVA model to take into account clustering effects are presented. Rate of uncovered struts was 8.6%, LSE 7.39 (95% CI 3.05–11.73), malapposed struts 2.2%, LSE 1.76 (95% CI 0.05–3.58), and protruding struts 2.9%, LSE 2.8 (95% CI 1.35–4.65). The proportion of uncovered malapposed struts was significantly higher compared to uncovered embedded struts (55.7% vs. 6.8%, p &lt; 0.01). In total, 5 (25%) PES were fully covered by neointima. No intracoronary thrombus or clinical events were detected. Conclusions Six months after implantation of a specific PES in patients with ACS, most of the stents were only partially covered with neointima, especially at sites of strut malapposition or protrusion. These findings emphasize the need for optimal stent apposition during implantation and for prolonged dual antiplatelet therapy.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>20605242</pmid><doi>10.1016/j.ijcard.2010.05.004</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-5273
ispartof International journal of cardiology, 2011-09, Vol.151 (2), p.155-159
issn 0167-5273
1874-1754
language eng
recordid cdi_proquest_miscellaneous_887756830
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Acute Coronary Syndrome - diagnosis
Acute Coronary Syndrome - surgery
Antineoplastic Agents, Phytogenic - pharmacology
Apposition
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular
Coronary Angiography
Coronary heart disease
Coronary Restenosis - diagnosis
Coronary Restenosis - etiology
Data processing
Diagnosis, Differential
Disease Progression
Drug-Eluting Stents - adverse effects
Female
Follow-Up Studies
Heart
Humans
Hyperplasia
Implants
Malapposition
Male
Medical sciences
Middle Aged
Myocarditis. Cardiomyopathies
Neointima
Neointima - complications
Neointima - pathology
OCT
Paclitaxel
Paclitaxel - pharmacology
Prognosis
Prospective Studies
Prosthesis Failure
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
restenosis
Statistical analysis
Statistics
Thrombosis
Time Factors
Tomography
Tomography, Optical Coherence - methods
Tunica Intima - pathology
title Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A50%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neointimal%20coverage%20and%20stent%20strut%20apposition%20six%20months%20after%20implantation%20of%20a%20paclitaxel%20eluting%20stent%20in%20acute%20coronary%20syndromes:%20An%20optical%20coherence%20tomography%20study&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Davlouros,%20Periklis%20A&rft.date=2011-09-01&rft.volume=151&rft.issue=2&rft.spage=155&rft.epage=159&rft.pages=155-159&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2010.05.004&rft_dat=%3Cproquest_cross%3E1221140287%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1221140287&rft_id=info:pmid/20605242&rft_els_id=S0167527310003542&rfr_iscdi=true